肺癌

1. Yang, Xin et al. “Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.” The New England journal of medicine vol. 379,9 (2018): e14. doi:10.1056/NEJMc1808251IF: 96.2 Q1

https://www.nejm.org/doi/10.1056/NEJMc1808251?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

 2.Chen, Jonathan H et al. “Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy.” Nature immunology vol. 25,4 (2024): 644-658. doi:10.1038/s41590-024-01792-2IF: 27.7 Q1

https://www.nature.com/articles/s41590-024-01792-2

 3. Wang, Yan et al. “Spatial transcriptomics delineates molecular features and cellular plasticity in lung adenocarcinoma progression.” Cell discovery vol. 9,1 96. 19 Sep. 2023, doi:10.1038/s41421-023-00591-7IF: 13.0 Q1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507052/

4. Huiyong Chen, Hongliang Liao, Longlong Gong et al. Multiplex Immunohistochemistry Applies to Examination of PD-1/PD-L1 on Immune Cells for Prognosis Prediction in Non-Small Cell Lung Cancer, 27 September 2021, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-929708/v1]

https://www.researchsquare.com/article/rs-929708/v1

5. Ghiringhelli, François et al. “Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.” EBioMedicine vol. 92 (2023): 104633. doi:10.1016/j.ebiom.2023.104633IF: 9.7 Q1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232659/